Dr Vanessa Cirulli, PSYD | |
250 Bon Air Rd, Greenbrae, CA 94904-1702 | |
(415) 473-6392 | |
Not Available |
Full Name | Dr Vanessa Cirulli |
---|---|
Gender | Female |
Speciality | Rehabilitation Counselor |
Location | 250 Bon Air Rd, Greenbrae, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396079653 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | (* (Not Available)) | Secondary |
225C00000X | Rehabilitation Counselor | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Vanessa Cirulli, PSYD Po Box 3556, Berkeley, CA 94703-0556 Ph: (302) 648-2595 | Dr Vanessa Cirulli, PSYD 250 Bon Air Rd, Greenbrae, CA 94904-1702 Ph: (415) 473-6392 |
News Archive
A new radiological diagnostic tool called stereo mammography allows clinicians to detect more lesions and could significantly reduce the number of women who are recalled for additional tests following routine screening mammography.
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
Drug company Eli Lilly has been given approval by the U.S. Food and Drug Administration (FDA) for its drug Gemzar to be used by women living with recurrent ovarian cancer.
The Centers for Disease Control and Prevention recommends that adults of all ages should engage in 150 or more minutes of moderate physical activity per week. Among adults 60 years of age or more, walking is the most common form of leisure-time physical activity because it is self-paced, low impact and does not require equipment.
MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that it has received a technology milestone payment from Novartis in connection with completion of the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland.
› Verified 2 days ago